The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. | Ann Intern Med;174(2): JC15, 2021 02. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.

Chagla, Zain.

Chagla Z; McMaster University, Hamilton, Ontario, Canada (Z.C.).

Ann Intern Med ; 174(2): JC15, 2021 02.

Article in English | MEDLINE | ID: covidwho-1067958

ABSTRACT

ABSTRACT

SOURCE CITATION Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;3832603-15. 33301246.

Subject(s)

COVID-19; Vaccines; BNT162 Vaccine; COVID-19 Vaccines; Humans; RNA, Messenger; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Intern Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Intern Med Year: 2021 Document Type: Article